Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-412-8400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.04 million
Profitability
Miscellaneous
Employees77
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Tocagen (NASDAQ:TOCA) Frequently Asked Questions
What is Tocagen's stock symbol?
Tocagen trades on the NASDAQ under the ticker symbol "TOCA."
How were Tocagen's earnings last quarter?
Tocagen Inc (NASDAQ:TOCA) announced its earnings results on Tuesday, May, 7th. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.01. The company earned $0.01 million during the quarter, compared to analysts' expectations of $2.01 million. Tocagen had a negative net margin of 294.74% and a negative return on equity of 108.08%. View Tocagen's Earnings History.
When is Tocagen's next earnings date?
What price target have analysts set for TOCA?
9 analysts have issued 12-month price targets for Tocagen's stock. Their forecasts range from $5.00 to $28.00. On average, they anticipate Tocagen's stock price to reach $17.50 in the next year. This suggests a possible upside of 281.3% from the stock's current price. View Analyst Price Targets for Tocagen.
What is the consensus analysts' recommendation for Tocagen?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tocagen.
What are Wall Street analysts saying about Tocagen stock?
Here are some recent quotes from research analysts about Tocagen stock:
- 1. According to Zacks Investment Research, "Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company's lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. " (5/17/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of Tocagen and our 12-month price target of $14.50 per diluted share. We derive our price target based on a risk-adjusted NPV analysis of projected Toca 511 + Toca FC revenues through 2030 assuming a 12% discount rate and a 2% terminal growth rate." (5/9/2019)
- 3. Cantor Fitzgerald analysts commented, "$28 PT EPS 1Q 2Q 3Q 4Q 2018A (0.65)A (0.81)A (0.02)A (0.96)A 2019E (0.87)E (0.90)E (0.92)E (0.78)E 2020E (0.81)E (0.81)E (0.80)E (0.58)E REV 1Q 2Q 3Q 4Q 2018A 0.0A 0.0A 18.0A 0.0A 2019E 0.0E 0.0E 0.0E 0.0E 2020E 0.0E 0.0E 0.0E 6.4E FY 2018A 2019E 2020E EPS (2.44)A (3.45)E (2.99)E (2.8)x REV 18.0A 0.0E 6.5E P/S 11.0x — 30.5x Summary: We are initiating coverage of Overweight rating and 12-month price target of $28. Tocagen focuses on cancer-specific gene therapy drugs utilizing a retroviral replicating vector (RRV) platform. 5 trial in recurrent high grade glioma (rHGG) is due in 2Q19 and 4Q19. In our view, Toca 511 & Toca FC could become an effective treatment option for these patients, where there is a significant unmet need with low survival rates." (4/25/2019)
Has Tocagen been receiving favorable news coverage?
Media coverage about TOCA stock has trended negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tocagen earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the next few days.
Who are some of Tocagen's key competitors?
Some companies that are related to Tocagen include NextCure (NXTC), Cyclerion Therapeutics (CYCN), Kalvista Pharmaceuticals (KALV), Albireo Pharma (ALBO), Savara (SVRA), Arcus Biosciences (RCUS), Assembly Biosciences (ASMB), Collegium Pharmaceutical (COLL), Achillion Pharmaceuticals (ACHN), Progenics Pharmaceuticals (PGNX), BioDelivery Sciences International (BDSI), Innate Pharma (IPHYF), Forty Seven (FTSV), Prothena (PRTA) and Dynavax Technologies (DVAX).
What other stocks do shareholders of Tocagen own?
Who are Tocagen's key executives?
Tocagen's management team includes the folowing people:
- Mr. Martin J. Duvall, CEO & Director (Age 57)
- Mr. Thomas E. Darcy, Co-Founder & Director (Age 68)
- Dr. Douglas J. Jolly, Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 71)
- Mr. Mark G. Foletta C.P.A., CPA, Exec. VP & CFO (Age 58)
- Dr. Harry E. Gruber, Founder, Adviser & Director (Age 66)
When did Tocagen IPO?
(TOCA) raised $80 million in an initial public offering on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO.
Who are Tocagen's major shareholders?
Tocagen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.14%), JPMorgan Chase & Co. (1.95%), Geode Capital Management LLC (1.13%), Northern Trust Corp (0.99%), Oxford Asset Management LLP (0.79%) and Morgan Stanley (0.61%). View Institutional Ownership Trends for Tocagen.
Which major investors are selling Tocagen stock?
TOCA stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Meeder Asset Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Tocagen.
Which major investors are buying Tocagen stock?
TOCA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rubric Capital Management LP, Morgan Stanley, Essex Investment Management Co. LLC, JPMorgan Chase & Co., J. Goldman & Co LP, Geode Capital Management LLC and Acadian Asset Management LLC. View Insider Buying and Selling for Tocagen.
How do I buy shares of Tocagen?
Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tocagen's stock price today?
One share of TOCA stock can currently be purchased for approximately $4.59.
How big of a company is Tocagen?
Tocagen has a market capitalization of $109.16 million and generates $18.04 million in revenue each year. The company earns $-48,960,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Tocagen employs 77 workers across the globe.
What is Tocagen's official website?
How can I contact Tocagen?
Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]
MarketBeat Community Rating for Tocagen (NASDAQ TOCA)
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
